Department of Biomedical Research, National Jewish Health, Denver, Colorado 80206; Center for Genes, Environment and Health, National Jewish Health, Denver, Colorado 80206; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado 80045.
Pulmonary and Critical Care, WakeMed Hospital, Raleigh, North Carolina 27610.
J Biol Chem. 2020 May 1;295(18):6236-6248. doi: 10.1074/jbc.RA119.011495. Epub 2020 Mar 16.
Although a robust inflammatory response is needed to combat infection, this response must ultimately be terminated to prevent chronic inflammation. One mechanism that terminates inflammatory signaling is the production of alternative mRNA splice forms in the Toll-like receptor (TLR) signaling pathway. Whereas most genes in the TLR pathway encode positive mediators of inflammatory signaling, several, including that encoding the MyD88 signaling adaptor, also produce alternative spliced mRNA isoforms that encode dominant-negative inhibitors of the response. Production of these negatively acting alternatively spliced isoforms is induced by stimulation with the TLR4 agonist lipopolysaccharide (LPS); thus, this alternative pre-mRNA splicing represents a negative feedback loop that terminates TLR signaling and prevents chronic inflammation. In the current study, we investigated the mechanisms regulating the LPS-induced alternative pre-mRNA splicing of the transcript in murine macrophages. We found that 1) the induction of the alternatively spliced form is due to alternative pre-mRNA splicing and not caused by another RNA regulatory mechanism, 2) splicing is regulated by both the MyD88- and TRIF-dependent arms of the TLR signaling pathway, 3) splicing is regulated by the NF-κB transcription factor, and 4) NF-κB likely regulates alternative pre-mRNA splicing rather than regulating splicing indirectly by altering transcription. We conclude that alternative splicing of may provide a sensitive mechanism that ensures robust termination of inflammation for tissue repair and restoration of normal tissue homeostasis once an infection is controlled.
尽管需要强烈的炎症反应来对抗感染,但最终必须终止这种反应,以防止慢性炎症。终止炎症信号的一种机制是 Toll 样受体 (TLR) 信号通路中产生替代的 mRNA 剪接形式。虽然 TLR 通路中的大多数基因编码炎症信号的正向调节剂,但包括编码 MyD88 信号衔接子的基因在内的几个基因也产生编码反应的显性负抑制剂的替代剪接 mRNA 异构体。这些具有负向作用的替代剪接异构体的产生是由 TLR4 激动剂脂多糖 (LPS) 刺激诱导的;因此,这种替代前体 mRNA 剪接代表了终止 TLR 信号并防止慢性炎症的负反馈回路。在本研究中,我们研究了调节 TLR 信号通路中 转录本 LPS 诱导的替代前体 mRNA 剪接的机制。我们发现:1)替代剪接 形式的诱导归因于替代前体 mRNA 剪接,而不是由另一种 RNA 调控机制引起的;2)剪接由 TLR 信号通路的 MyD88 和 TRIF 依赖性臂调节;3)剪接受 NF-κB 转录因子调节;4)NF-κB 可能通过改变 转录间接调节 剪接,而不是通过改变 转录间接调节 剪接。我们得出结论, 的替代剪接可能提供一种敏感的机制,以确保一旦感染得到控制,炎症就能迅速终止,从而进行组织修复和恢复正常组织内稳态。